NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 327 filers reported holding NOVOCURE LTD in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $249,996 | -36.2% | 6,024 | -7.5% | 0.00% | -100.0% |
| Q1 2023 | $391,752 | -15.3% | 6,514 | +3.3% | 0.00% | 0.0% |
| Q4 2022 | $462,472 | +23023.6% | 6,305 | +20916.7% | 0.00% | – |
| Q1 2022 | $2,000 | -99.3% | 30 | -97.8% | 0.00% | -100.0% |
| Q2 2021 | $297,000 | +21.2% | 1,341 | -27.7% | 0.00% | – |
| Q1 2021 | $245,000 | -75.5% | 1,856 | -67.9% | 0.00% | -100.0% |
| Q4 2020 | $1,001,000 | +5788.2% | 5,787 | +478.7% | 0.00% | – |
| Q2 2017 | $17,000 | -87.6% | 1,000 | -94.1% | 0.00% | -100.0% |
| Q1 2017 | $137,000 | +37.0% | 16,857 | +32.1% | 0.00% | 0.0% |
| Q4 2016 | $100,000 | +11.1% | 12,757 | +20.9% | 0.00% | 0.0% |
| Q3 2016 | $90,000 | +45.2% | 10,550 | +99.1% | 0.00% | – |
| Q2 2016 | $62,000 | +1966.7% | 5,298 | +2549.0% | 0.00% | – |
| Q1 2016 | $3,000 | -25.0% | 200 | 0.0% | 0.00% | – |
| Q4 2015 | $4,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $77,833,000 | 15.51% |
| HARTLINE INVESTMENT CORP/ | 302,194 | $67,033,000 | 8.47% |
| Darsana Capital Partners LP | 700,000 | $155,274,000 | 4.42% |
| MORGAN JESS S & CO INC | 23,775 | $5,274,000 | 3.47% |
| Soleus Capital Management, L.P. | 98,975 | $21,955,000 | 3.38% |
| Montanaro Asset Management Ltd | 116,650 | $25,875,000 | 3.26% |
| Taylor Frigon Capital Management LLC | 31,035 | $6,884,000 | 2.15% |
| Rhenman & Partners Asset Management AB | 120,000 | $26,618,000 | 1.81% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $2,218,000 | 1.33% |
| Derbend Asset Management | 5,789 | $1,284,000 | 1.20% |